Participant flow

A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis · Source last updated 2013-11-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients received tocilizumab (TCZ) 8 mg/kg intravenously every 4 weeks.

   id

   FG000

   title

   Tocilizumab 8 mg/kg

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         96

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         10

      type

      Death

   3. reasons

      1. group Id

         FG000

         num Subjects

         21

      type

      Insufficient Therapeutic Response

   4. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Protocol Violation

   5. reasons

      1. group Id

         FG000

         num Subjects

         41

      type

      Refused Treatment

   6. reasons

      1. group Id

         FG000

         num Subjects

         9

      type

      Failure to Return

   7. reasons

      1. group Id

         FG000

         num Subjects

         5

      type

      Withdrawal by Subject

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         538

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         355

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         183

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice